logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Sectors
ZURA
Zura Bio Limited
5.63
1 x 5.57
1 x 5.95
bid
ask
-
0.15
2.60%
1 @ 04:00 PM
5.52 -0.11 (1.95%)
Ytd7.44%
1y254.09%
5.56
day range
5.82
1.57
52 week range
7.44
Open5.80Prev Close5.78Low5.56High5.82Mkt Cap534.84M
Vol0.00Avg Vol1.08MEPS-1.09P/E-5.17Forward P/E-3.22
Beta0.14Short Ratio14.48Inst. Own58.01%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning05-0750-d Avg4.89200-d Avg5.071yr Est14.29

ZURA News

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
gurufocus.com
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing no

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
businesswire.com
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotech

Zura Bio Limited (NASDAQ:ZURA) Receives $10.75 Average Target Price from Brokerages
defenseworld.net
Zura Bio Limited (NASDAQ:ZURA) Receives $10.75 Average Target Price from Brokerages

Shares of Zura Bio Limited (NASDAQ: ZURA - Get Free Report) have received an average rating of "Mode

Zura Bio (NASDAQ:ZURA) Trading 5.3% Higher – Here’s Why
defenseworld.net
Zura Bio (NASDAQ:ZURA) Trading 5.3% Higher – Here’s Why

Zura Bio Limited (NASDAQ: ZURA - Get Free Report)'s share price rose 5.3% during trading on Friday.

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy
benzinga.com
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy

On Wednesday, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
businesswire.com
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc)

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical stage biotech

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clini

Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
businesswire.com
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotech

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
businesswire.com
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotech

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clini

Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of “Moderate Buy” by Analysts
defenseworld.net
Zura Bio Limited (NASDAQ:ZURA) Given Consensus Rating of “Moderate Buy” by Analysts

Zura Bio Limited (NASDAQ: ZURA - Get Free Report) has been assigned an average rating of "Moderate B

Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $11.60
defenseworld.net
Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $11.60

Zura Bio Limited (NASDAQ: ZURA - Get Free Report) has been given a consensus rating of "Moderate Buy

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
businesswire.com
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a cl

Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
businesswire.com
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a cl

Zura Bio to Participate in Upcoming Investor Conferences
businesswire.com
Zura Bio to Participate in Upcoming Investor Conferences

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the

Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
businesswire.com
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a cl

Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
businesswire.com
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA), a clinical-st

Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
businesswire.com
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology co

Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D.
businesswire.com
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula,

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the

Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026
defenseworld.net
Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026

Zura Bio (NASDAQ: ZURA) outlined its near-term clinical milestones and strategy at Guggenheim Securi
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
benzinga.com
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announce